Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer

被引:93
作者
Colleoni, M.
Rotmensz, N.
Maisonneuve, P.
Sonzogni, A.
Pruneri, G.
Casadio, C.
Luini, A.
Veronesi, P.
Intra, M.
Galimberti, V.
Torrisi, R.
Andrighetto, S.
Ghisini, R.
Goldhirsch, A. .
Viale, G.
机构
[1] Ist Europeo Oncol, Dept Med, Res Unit Med Senol, I-20141 Milan, Italy
[2] Unit Quality Control, Milan, Italy
[3] Div Epidemiol & Biostat, Milan, Italy
[4] Div Pathol & Lab Med, Milan, Italy
[5] European Inst Oncol, Div Senol, Milan, Italy
[6] Univ Milan, Sch Med, Milan, Italy
关键词
peritumoral vascular invasion; breast cancer; prognostic factor;
D O I
10.1093/annonc/mdm268
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The clinical relevance of the degree of peritumoral vascular invasion (PVI) in patients with no or limited involvement of the axillary nodes is unknown. Materials and methods: 2606 consecutive patients with pT1-3, pNO (1586)-1a (1020) and MO, operated and counseled for medical therapy from 1/2000 to 12/2002, were prospectively classified according to the degree of PVI: absent (2017, 77.4%), focal (368, 14.1%), moderate (51, 2.0%) and extensive (170, 6.5%). Results: Patients with extensive PVI were more likely to be younger, to have larger tumors, high tumor grade, axillary-positive nodes, high Ki-67 expression and HER2/neu over-expression compared with patients having less PVI (P for trend, <0.0001). In patients with node-negative disease a statistically significant difference in disease-free survival (DIPS), risk of distant metastases and overall survival (OS) was observed at the multivariate analysis for extensive PVI versus no PVI (hazard ratios: 2.11, 95% Cl, 1.02 to 4.34, P = 0.04 for DFS; 4.51, 95% Cl, 1.96 to 10.4, P< 0.001 for distant metastases; 3.55, 95% Cl, 1.24 to 10.1, P = 0.02 for OS). Conclusions: The extent of vascular invasion should be considered in the therapeutic algorithm in order to properly select targeted adjuvant treatment.
引用
收藏
页码:1632 / 1640
页数:9
相关论文
共 30 条
[1]  
[Anonymous], 1993, Tumors of the mammary gland
[2]   Triple-negative breast cancer: therapeutic options [J].
Cleator, Susan ;
Heller, Wolfgang ;
Coombes, R. Charles .
LANCET ONCOLOGY, 2007, 8 (03) :235-244
[3]   Prediction of response to primary chemotherapy for operable breast cancer [J].
Colleoni, M ;
Orvieto, E ;
Nolé, F ;
Orlando, L ;
Minchella, I ;
Viale, G ;
Peruzzotti, G ;
Robertson, C ;
Noberasco, C ;
Galimberti, V ;
Sacchini, V ;
Veronesi, P ;
Zurrida, S ;
Orecchia, R ;
Goldhirsch, A .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (04) :574-579
[4]   Duration of adjuvant chemotherapy for breast cancer:: a joint analysis of two randomised trials investigating three versus six courses of CMF [J].
Colleoni, M ;
Litman, HJ ;
Castiglione-Gertsch, M ;
Sauerbrei, W ;
Gelber, RD ;
Bonetti, M ;
Coates, AS ;
Schumacher, M ;
Bastert, G ;
Rudenstam, CM ;
Schmoor, C ;
Lindtner, J ;
Collins, J ;
Thürlimann, B ;
Holmberg, SB ;
Crivellari, D ;
Beyerle, C ;
Neumann, RLA ;
Goldhirsch, A .
BRITISH JOURNAL OF CANCER, 2002, 86 (11) :1705-1714
[5]   Early distant relapse in 'node-negative' breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour [J].
Colpaert, C ;
Vermeulen, P ;
Jeuris, W ;
van Beest, P ;
Goovaerts, G ;
Weyler, J ;
Van Dam, P ;
Dirix, L ;
Van Marck, E .
JOURNAL OF PATHOLOGY, 2001, 193 (04) :442-449
[6]   Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers [J].
de Mascarel, I ;
Bonichon, F ;
Durand, M ;
Mauriac, LH ;
MacGrogan, G ;
Soubeyran, I ;
Picot, V ;
Avril, A ;
Coindre, JM ;
Trojani, M .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (01) :58-65
[7]  
Domagala W, 1996, CLIN CANCER RES, V2, P147
[8]  
Elston C W, 2002, Histopathology, V41, P151
[9]   2 MONTHS OF DOXORUBICIN-CYCLOPHOSPHAMIDE WITH AND WITHOUT INTERVAL REINDUCTION THERAPY COMPARED WITH 6 MONTHS OF CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN POSITIVE-NODE BREAST-CANCER PATIENTS WITH TAMOXIFEN-NONRESPONSIVE TUMORS - RESULTS FROM THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT B-15 [J].
FISHER, B ;
BROWN, AM ;
DIMITROV, NV ;
POISSON, R ;
REDMOND, C ;
MARGOLESE, RG ;
BOWMAN, D ;
WOLMARK, N ;
WICKERHAM, DL ;
KARDINAL, CG ;
SHIBATA, H ;
PATERSON, AHG ;
SUTHERLAND, CM ;
ROBERT, NJ ;
AGER, PJ ;
LEVY, L ;
WOLTER, J ;
WOZNIAK, T ;
FISHER, ER ;
DEUTSCH, M .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) :1483-1496
[10]   Breast carcinoma in elderly women -: Features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients [J].
Gennari, R ;
Curigliano, G ;
Rotmensz, N ;
Robertson, C ;
Colleoni, M ;
Zurrida, S ;
Nolé, F ;
de Braud, F ;
Orlando, L ;
Leonardi, MC ;
Galimberti, V ;
Intra, M ;
Veronesi, P ;
Renne, G ;
Cinieri, S ;
Audisio, RA ;
Liuini, A ;
Orecchia, R ;
Viale, G ;
Goldhirsch, A .
CANCER, 2004, 101 (06) :1302-1310